On May 15, 2020 Peijia Medical Limited (9996.HK) was listed on the Main Board of the Hong Kong Stock Exchange. The Hong Kong Public Offering had been subscribed by 1,184.41 times, making it the most popular offering by funds frozen so far in 2020.
Huatai Financial was the Joint Sponsor, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager for the deal. Peijia Medical issued approximately 152.5 million shares worldwide at an issue price of HK$15.36 per share, raising a total amount of HK$2.34 billion, (before the exercise of the over-allotment option).
Peijia Medical Limited is a leading domestic player in each of the transcatheter valve therapeutic medical device market and neurointerventional procedural medical device market in China. It focuses on the high-growth interventional procedural medical device market in China. Peijia Medical has built a synergetic platform encompassing research and development, manufacturing and commercialization capabilities as well as a comprehensive product portfolio. Peijia Medical is committed to become a world-renowned medical device company that provides total treatment solutions for structural heart and neurovascular diseases.